UMaine med device spinoff Neuright receives $225K tech transfer award

Neuright Inc., a University of Maine biotech spinoff focused on the early diagnosis and treatment of peripheral neuropathy, was awarded $225,000 under the National Science Foundation’s Small Business Technology Transfer program to develop its technology for delivery to market.

Peripheral neuropathy, a condition in which nerve fibers die back from the skin, is estimated to affect more than 20 million people in the U.S. and can cause symptoms including pain, numbness and loss of limb control, according to a news release.

Diabetes is the leading cause of peripheral neuropathy. Up to 70% of the 34 million Americans with diabetes will also have peripheral neuropathy. Wide-ranging, variable symptoms make peripheral neuropathy difficult to diagnose, and while there is no cure, early intervention and treatment can help patients minimize the often-debilitating effects. Read more

Related Posts

UNE undergraduate receives BioME grant to study rare lobster larvae

A University of New England undergraduate student has received a $5,000 grant from the Bioscience Association of Maine (BioME) to fund...

23 May 2024

New initiative unites Maine’s innovators to bolster STEM research and workforce

An $8 million grant from the National Science Foundation will fund a four-year initiative led by the University of Maine to bolster STEM...

15 May 2024

Jackson Lab hires its first-ever chief scientific officer

Jackson Laboratory, based in Bar Harbor, has hired Mary Dickinson, a globally recognized geneticist, developmental biologist, and bioengineer, as executive vice...

13 May 2024